Administration of Angiotensin-Converting Enzyme Inhibitors and β-Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?

BACKGROUND. Adjuvant trastuzumab therapy improves the outcome of patients with early breast cancer (EBC) and overexpression of human epidermal growth factor receptor 2 (HER2). However, it is potentially cardiotoxic. This study aims to evaluate the relationship between the use of angiotensin-converti...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Oliva, Stefano, Cioffi, Giovanni, Frattini, Silvia, Simoncini, Edda Lucia, Faggiano, Pompilio, Boccardi, Lidia, Pulignano, Giovanni, Fioretti, Agnese Maria, Giotta, Francesco, Lestuzzi, Chiara, Maurea, Nicola, Sabatini, Silvia, Tarantini, Luigi
التنسيق: Artigo
اللغة:Inglês
منشور في: AlphaMed Press 2012
الموضوعات:
Breast Cancer
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399646/
https://ncbi.nlm.nih.gov/pubmed/22673631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0445
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة